Asana Biosciences, LLC

Merck Sharp + Dohme Corp.

Schering Corporation

Endo Pharmaceuticals Inc.

Merck Sharp & Dohme Corp. and Canji, Inc.

Abs Development 1, Inc.

Pharmacopeia Inc.

Endo Pharmaceuticals Solutions Inc.

Tony Priestley

John J Baldwin

Aranapakam Mudumbai Venkatesan

Roger Astbury Smith

Arthur G Taveras

Scott Kevin Thompson

Younong Yu

Hui-Yin Li

Purakkattle J Biju

Ashis K Saha

Jianhua Chao

Junying Zheng

Sandeep Gupta

Sonali Rudra

Carl Henry Behrens

Cynthia J Aki

J Robert Merritt

Nicholas James Laping

Gaifa Lai

Daniel Lundell

Mrinal Kundu

Jay S Fine

Mrinalkanti Kundu

Suvadeep Nath

Minglang Wu

John C Hunter

Sameer Goregaoker

Yigang He

Dipanwita Chatterjee

Arun Kuma Hajra

Scott Thompson

Angelo Reggiani

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

P2X3 and/or P2X2/3 compounds and methods

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

P2Xand/or P2Xcompounds and methods

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. 

[object Object]

The present application provides methods of using the aminoindane compounds of formula (I) or (II) in treating an overactive bladder or interstitial cystitis by administering one or more of the compounds to a patient. 

Use of aminoindane compounds in treating overactive bladder and interstitial cystitis

The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine. 

Cyclohexylamines

The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine. 

Aminoindane compounds and use thereof in treating pain

The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Na1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.

Growing community of inventors

West Chester, PA, United States of America

Tony Priestley